Mans International “Be Your Own Boss” Program is designed to help people from all walks of life around the world who are committed to changing their way of thinking, improving their abilities, and achieving financial freedom and time freedom.
Before You Start
First of all, I’m sorry to tell you that it takes a long time to realize financial freedom and time freedom. If for whatever reason, you have obtained a large amount of wealth, it doesn’t mean that you achieved financial freedom automatically. Because you may not have the ability and psychological capacity to manage large amounts of wealth, the money will be consumed at a rate you can’t imagine.
You might say, can I just ask a financial professional to help me take care of my wealth? The question I asked was do you have the ability to select an outstanding and suitable professional?
If you feel that you ALREADY have independent thinking and various skills, then you do not need to participate in this program! All the best!
Our Values
If you DON’T agree with our values, please do not disturb！
Check Mans International “Be Your Own Boss” program values:
You can either send an email to info@mansinternational.com and we will send you the latest content regularly.
Before You Go
Every year we make plans. Every day we receive tons of information and learn a lot of knowledge, but why most people still can’t make choices that are beneficial to themselves in the long run, achieve their goals, and become a better version of themselves?
What Huawei’s Tau Scaling Law and DeepSeek V4 Reveal About the New AI Moat
Constraint Is the Ultimate Strategy Test
The AI race is entering a new phase. For years, AI advantage seemed to belong to those who could scale the biggest models, compute, chips, data centers, and capital. But DeepSeek and Huawei point to a different strategic reality.
The next AI advantage may not come from one isolated breakthrough. It may come from the ability to redesign the whole system under constraints.
That is why they matter to founders. They are not only technology stories. They are scenario maturity stories.
They show that real AI defensibility comes from system alignment: model, chip, data, workflow, cost structure, infrastructure, regulation, and market readiness working together.
This is the shift the Scenario Maturity Assessment Framework, or SMAF, is designed to evaluate: not whether a technology is impressive in isolation, but whether the surrounding scenario is mature enough to convert that technology into commercial power.
Huawei’s Tau Scaling Law: From Component Thinking to System Thinking
At IEEE ISCAS 2026, Huawei’s He Tingbo introduced Tau Scaling Law, a proposed path for semiconductor progress as Moore’s Law becomes harder to sustain.
The strategic idea is simple: progress no longer depends only on making each component smaller. It also depends on making the whole system faster, better connected, and more coordinated.
Huawei’s Tau Scaling Law: From Component Thinking to System Thinking
For decades, chips improved through component-level scaling: smaller nodes, more transistors, higher density, and lower cost per computation. But when physical limits and geopolitical constraints restrict the old path, the question changes.
Can performance improve through architecture, integration, packaging, interconnects, software optimization, and full-stack coordination? Huawei’s answer is yes.
Whether every technical claim is fully validated remains to be seen. But the strategic signal is clear: when the direct path is blocked, advantage comes from redesigning the system.
This is why Huawei’s Tau Scaling Law matters beyond semiconductors. It reflects a broader strategic shift from component superiority to system maturity — a lesson every founder and investor should understand.
DeepSeek V4: From Model Power to Cost-Performance Fit
DeepSeek shows the same shift from the model side. The real lesson is not simply that China has produced another strong AI model. It is that model efficiency, hardware adaptation, and cost compression are starting to work together in commercially meaningful ways.
DeepSeek V4’s reported adaptation to Huawei Ascend chips signals a larger ecosystem strategy: models, domestic hardware, infrastructure, and cost-performance logic evolving together. That is different from a pure model race.
DeepSeek V4: From Model Power to Cost-Performance Fit
A pure model race asks: Who has the most powerful model?
A scenario maturity lens asks: Where can intelligence be deployed reliably, affordably, repeatedly, and profitably?
This is the more important question for founders.
Because cheaper intelligence does not automatically create a better business. Lower inference cost does not automatically create willingness to pay. Open-source momentum does not automatically create defensibility.
The real question is whether a specific market scenario is mature enough to turn intelligence into revenue, retention, workflow advantage, or strategic control.
That is where SMAF becomes useful.
The New AI Moat Is Scenario Maturity
DeepSeek and Huawei challenge a dangerous assumption in the AI application layer: that access to a strong model is enough. It is not.
As foundational intelligence becomes cheaper, faster, and more widely available, the moat shifts from model access to scenario maturity.
The New AI Moat Is Scenario Maturity
In SMAF, a mature AI scenario is not defined by technical excitement. It is defined by alignment across four dimensions:
Narrative Maturity: Can users, buyers, and investors quickly understand why this matters now?
Business Maturity: Who pays, why now, and what budget is unlocked?
Workflow Maturity: Does the AI fit how users actually work, decide, buy, and adopt?
Data Maturity: Can the system learn from relevant, repeatable data?
This is why many AI startups fail despite impressive demos. They build around capability before proving scenario maturity.
DeepSeek and Huawei show a different discipline: both respond to constraints through system design.
DeepSeek addresses compute and cost constraints through model efficiency and hardware adaptation. Huawei addresses semiconductor constraints through architecture, integration, and full-stack optimization.
The lesson for founders is not to copy them. It is to identify your own constraint. Is your real bottleneck model quality, data access, workflow adoption, compliance, trust, distribution, cost, budget ownership, or integration? Until you know the constraint, you do not know the strategy.
Constraint does not kill strategy. Constraint reveals strategy.
Constraint reveals strategy
If you are building or investing in the AI application layer, SMAF helps answer a harder question: Which scenario is mature enough to turn intelligence into durable value?
At Mans International, I work with a selected group of founders and investors to assess when an AI opportunity has matured enough to build a real business — and where East‑West ecosystem gaps offer strategic advantage.
Oura’s confidential IPO filing and reported $11 billion valuation may look like a wearable hardware milestone.
They are more than that.
They are a live stress test for how technology companies turn commoditized sensors into defensible, recurring value. The smart ring market is not simply an engineering race; it is a textbook case study in the Scenario Maturity Assessment Framework (SMAF).
This is why smart rings are a powerful case study for the Scenario Maturity Assessment Framework — SMAF Compass™.
The Four Pillars of the SMAF Compass
Founders do not usually fail because their technology is weak. They fail because they try to execute a strategy that the market scenario is not mature enough to support.
This is the core logic behind the SMAF Compass™, developed by Mans International: a strategic lens for evaluating whether a specific commercial scenario can convert technology into trust, usage, revenue, and defensible value.
The Mans International SMAF Compass
At a public level, the framework examines four visible dimensions of scenario maturity:
Narrative Maturity: Can the company translate complex tech into a clear, credible, and urgent story that customers, investors, and partners act on?
Business Maturity: Who actually buys — and why now? Is the pricing model aligned with user tolerance?
Workflow Maturity: Can this work in the real world — at scale — without friction?
Data Maturity: Does the system improve itself with use? Does data create an escalating switching cost?
1. Oura’s Real Moat Is Not Titanium. It Is Data & Narrative Maturity.
Oura did not become valuable because it built a beautiful ring. The ring is merely the physical entry point. The intelligence layer is the actual business.
Oura’s projected 2026 revenue of $1.5 billion to $2 billion, with an estimated 80/20 hardware-to-SaaS mix, proves its mastery of the SMAF engine:
Narrative & Business Maturity: Oura shifted the story from “step counting” to “readiness and recovery.” Its $5.99/month subscription model is a strategic bet that users will pay continuously if the product helps them decode their own bodies.
Data & Workflow Maturity: This creates a closed-loop flywheel: Biometric Data → AI Interpretation → Behaviour Change → Recurring Engagement → Subscription Revenue
Oura’s Closed-Loop Flywheel
Break any link, and the model collapses. If the insight is generic (Data failure), the habit does not form (Workflow failure), subscription churn rises, and the R&D flywheel slows. Oura’s IPO validates that consumer health hardware can achieve full SMAF alignment.
2. Smart Rings Are Splitting Into Three Commercial Scenarios
The mistake many founders make is treating smart rings as a single market. They are not. The same form factor now supports three distinct commercial scenarios, each requiring a different maturity foundation:
Smart Rings Are Splitting Into Three Commercial Scenarios
The danger for founders isn’t choosing the wrong product; it’s choosing a business model that their specific scenario cannot support.
3. China: The Ultimate Stress Test for Scenario Maturity
China makes the necessity of the SMAF visible. Oura’s limited active presence in the region is not a market oversight — it is a profound scenario mismatch.
While Oura’s model thrives in the West’s personal health intelligence scenario, attempting to port it to China causes the SMAF compass to spin wildly. The market sits at the intersection of four unique forces — manufacturing speed, data infrastructure, regulatory complexity, and platform behaviour — each demanding a completely reconfigured playbook:
China: The Ultimate Stress Test for Scenario Maturity
1. Business Maturity (Manufacturing Speed & Subscription Friction):
Western consumers accept buying a premium device and paying a monthly fee. A Chinese consumer asks: Why pay a subscription after buying the hardware? This resistance is compounded by Shenzhen’s ODM (Original Design Manufacturer) infrastructure, which allows local competitors to move from concept to a functional commercial product with low seed capital. When local hardware is cheap and fast, competing on hardware margins alone collapses into a race to zero.
2. Data Maturity (The PIPL Wall):
Health data is not ordinary data. China’s Personal Information Protection Law (PIPL) and Data Security Law create strict boundaries around biometric information, local storage, consent, and cross-border transfer. A foreign healthtech company cannot simply import its Western cloud architecture and expect its data loop to function legally.
3. Workflow Maturity (Regulatory Timelines):
Regulation dictates scale. If a smart ring’s claims move from wellness tracking into diagnostic utility, the product may trigger China’s NMPA medical device pathway. That abruptly changes the entire commercialization timeline, adding massive friction to real-world workflow and deployment.
4. Narrative Maturity (The Ecosystem Node):
Chinese digital behaviour is deeply ecosystem-driven. Consumers expect seamless, free integration with WeChat, Alipay, domestic smartphone ecosystems, and local fitness communities. To win, a company’s narrative must shift from selling a standalone “individual health tracker” to offering an “ambient digital node.”
This is why Oura’s Western strategy does not automatically travel. Its subscription strategy is powerful in a market where users value individualized health coaching and accept monthly digital services.
But in China, a winning strategy requires a completely redesigned scenario: free core features, localized data infrastructure, native ecosystem integration, regulatory clarity, and tiered monetization.
That is not a translation problem. It is a different scenario.
Closing: The Ring Is Only the Surface
The smart ring market is not rewarding the company with the sleekest hardware alone.
It is rewarding the company that understands how a device becomes a habit, how a habit becomes trust, and how trust becomes defensible value.
Oura’s IPO validates one mature scenario: premium health intelligence supported by recurring revenue.
China tests another: localized integration, regulatory trust, ecosystem behaviour, and lower-friction monetization.
The product may look the same. The commercial logic is not.
This is the lesson for founders and investors far beyond wearables. In the AI era, technology alone does not create defensibility. The moat belongs to those who understand where the market is truly ready to absorb intelligence, pay for it, and build new behaviour around it.
Technology does not scale globally by copying the product. It scales by matching the scenario.
That is Scenario Intelligence.
Are you building at the intersection of hardware, AI, and global markets? Do not wait for a costly market launch to find the fracture in your business model. Reach out to Mans International for a scenario maturity audit of your current product roadmap.
In the age of AI, starting a company has never been easier. Building one that wins has never been harder.
Execution is no longer scarce. AI can write code, produce content, and automate workflows at speeds once unimaginable. But when everyone can move faster, speed is no longer the edge.
The new scarcity is scenario intelligence: the founder’s ability to judge which market context is ready, which customer pain is worth serving, which workflow can absorb AI, and which problem is truly worth amplifying.
That is the quiet brutality of this era: experimentation is getting cheaper, but strategic misjudgment is becoming more expensive.
The next decade won’t belong to founders with the most resources. It will belong to those who can assess the maturity of a scenario before they scale.
I. The One-Person Company Is Not a Solo Act
Andrej Karpathy has compared large language models to something like a “fresh college graduate”: broadly read, astonishingly capable, but still lacking deep real-world experience.
That analogy is important for founders.
AI can help you execute faster. It can write code, produce content, analyze data, draft a strategy, automate workflows, and compress tasks that once required a full team.
This is why the rise of the One-Person Company is so powerful — and so often misunderstood.
The One-Person Company
It is not simply about one person replacing a team. It is about a deeper structural shift: once execution becomes massively amplified by AI, the founder’s judgment becomes the bottleneck.
The founder’s question shifts from: “Can I get this done?” to: “What exactly should I be building?” And more importantly: “Is this scenario mature enough to deserve my time, capital, and AI leverage?”
With AI, founders are no longer just operators. They become commanders of an invisible execution army.
But an army is only as valuable as the judgment directing it.
Without scenario intelligence, you are not a company of one. You are just noise moving faster.
II. Narrow Startups: Go Deep, Not Wide
This is where the Narrow Startup becomes essential.
As Anish Acharya at a16z argued in 2025, the next wave of startups will not win by serving everyone. They will win by going deep: solving a painful, specific problem so well that a narrow group of users is willing to pay significantly more.
Narrow Startups
The insight is simple: premium AI products can break the old consumer software ceiling because they deliver what he calls “100x leaps” for specific users.
These are not mass-market tools with slightly better features. They are mission-critical systems for users whose pain, ambition, or workflow intensity makes the product worth paying for.
That changes how founders should think about market size.
Narrow does not mean small. Narrow means dense.
A Narrow Startup asks: Which specific group has a painful, frequent, economically meaningful problem — and can we become the default intelligence layer inside that context?
That is the real opportunity in AI.
III. Medvi: A Narrow Startup Case Study — and a Warning
Medvi shows both the promise and the risk of the Narrow Startup model.
The U.S.-based telehealth company sits at the intersection of GLP-1 weight-loss drugs, direct-to-consumer healthcare, and AI-enabled operations. According to Business Insider, Medvi reported $401 million in revenue and $65 million in profit last year, with projected sales of $1.8 billion this year, all with an extremely lean team.
The headline is tempting: “One tiny team used AI to build a massive business.” But that misses the deeper lesson.
Medvi did not build a general AI health platform. It entered a narrow, high-demand scenario: consumers seeking easier access to weight-loss treatment, GLP-1 medications, asynchronous care, and ongoing support.
Patients were not looking for “AI.” They were looking for access, convenience, privacy, affordability, continuity, and results.
That is what made the scenario commercially powerful.
AI mattered because it helped compress the operating model. It could support marketing, content, customer communication, internal workflows, and software development, while external licensed partners handled clinical care, pharmacy fulfillment, and logistics.
In other words, technology was not just a feature. It changed the company’s cost structure and operating rhythm.
Medvi Use Case
But Medvi also shows the danger of confusing growth with readiness.
Business Insider reported that Medvi’s growth relied heavily on advertising and affiliate marketing, and raised allegations of AI-generated doctor personas and misleading claims. The FDA also issued a warning letter concerning false or misleading representations related to compounded semaglutide and tirzepatide products.
That is where the case becomes strategically important.
Medvi shows that AI can collapse organizational costs and amplify growth velocity. But in healthcare, speed is not durability.
Growth must be matched by trust, operational discipline, and regulatory credibility. When execution moves faster than the surrounding environment can absorb, momentum becomes fragile.
That is the real warning of Medvi: AI can accelerate a business, but it cannot compensate for a scenario that is not ready to scale.
IV. Why Scenario Intelligence Is the Moat
Technology will keep improving.
Models will become cheaper, faster, and more capable. Interfaces will become easier to build. Agentic workflows will become more common. Many technical advantages will compress over time.
But deep scenario understanding does not commoditize so easily.
It grows through immersion: observing users, understanding incentives, mapping budgets, identifying hidden friction, and knowing which pain is urgent enough to trigger action.
That kind of judgment cannot be downloaded overnight.
This is why scenario intelligence becomes the founder’s moat.
Narrowness is the entrance. Context is the container of value.
Scenario intelligence is the founder’s ability to know which container is ready.
V. From Insight to Action
If your AI product is generating interest but not conversion, the problem may not be your technology. It may be your scenario maturity.
At Mans International, we help technology founders and investors pressure-test where value is truly trapped, whether the market is ready to absorb the product, and what must change before customers, investors, or strategic partners move.
If you are building in AI, health tech, or another high-stakes market, reach out, and I’ll share a Scenario Maturity Self-Assessment Checklist to help you evaluate your buyer, workflow, data loop, narrative, and trust architecture before you scale.
Because in the AI era, the winners will not be the companies that execute the fastest. They will be the companies that know exactly which scenario is ready to win.
这个区别，对我们中国科技创始人来说至关重要。Formation Bio 从来没想过要颠覆药企的整个研发体系，而是精准切入一个“有预算、有紧迫感、有战略压力”的昂贵瓶颈——临床推进环节，这就是我们一直强调的“场景成熟度思维”：不盲目追求技术颠覆，而是找到产业里真实存在的、未被满足的成熟场景，用技术解决具体痛点，才能真正实现价值闭环。
Most AI health startups ask the wrong question: “What can our technology do?”
Formation Bio asked something far more valuable: “Where is value already trapped — and who has the budget to unlock it?”
That single shift explains why Formation Bio has become one of the most closely watched AI-native drug development companies. The company has reportedly raised about $615 million, reached a valuation of around $1.8 billion, and attracted investors including Sam Altman, Sequoia Capital, and Andreessen Horowitz.
But the real lesson is not that Formation Bio “uses AI.” The real lesson is that Formation Bio chose a mature commercial scenario before scaling the technology. That is what most AI health startups miss.
The Real Bottleneck Was Never Drug Discovery
For years, the dominant AI drug development story has been about discovery:
Find new targets
Generate new molecules
Predict biological behaviour faster than humans
But Formation Bio’s founder and CEO, Ben Liu, saw a different bottleneck.
“Pharma does not lack promising molecules. It lacks a faster, cheaper, more reliable way to move drugs through clinical development.”
Clinical trials are slow, expensive, operationally complex, and filled with execution risk. TIME recently reported that Formation Bio is focused on accelerating administrative and analytical tasks related to trials. Formation Bio:
Buys or in-licenses “stalled” assets — drugs already discovered but shelved by big pharma due to budget cuts, strategic shifts, or portfolio pruning
Uses proprietary AI to “stress-test” and accelerate trials — optimizing patient recruitment, site selection, and protocol design
De-risks and out-licenses — creating value through speed, not novelty
That distinction matters. Formation Bio is not trying to replace pharma’s entire R&D system. It is attacking a painful, expensive bottleneck in a system already facing budget constraints, urgency, and strategic pressure.
That is Scenario Maturity Thinking.
What Is Scenario Maturity?
Scenario Maturity is the difference between a technology that looks impressive and a business that can actually convert.
A mature scenario has three pillars:
The Scenario Maturity Compass
1. Business Maturity
Who actually buys?
Who owns the budget?
Why would they act now?
2. Workflow Maturity
Can the solution fit into real-world operations?
Or does it require customers to change behaviour, rebuild infrastructure, and take on new risk?
3. Data Maturity
Does usage create better data?
Does better data improve the system?
Does that improvement compound into a defensible advantage?
When these three pillars align, revenue has a pathway. When one breaks, even excellent technology can stall.
This is why I often tell founders: technology does not generate revenue on its own. Scenario maturity creates the conditions for revenue.
Clear Buyer Convergence: Who Actually Pays?
Many AI health startups fail because they build for users rather than buyers.
They build for clinicians, patients, researchers, or health platforms — but cannot answer the most important commercial question: Who signs the purchase order?
Formation Bio identified their buyer early: Pharma business development & clinical operations teams at companies like Sanofi and Eli Lilly.
Have multi-billion dollar R&D budgets
Face intense pressure to improve time-to-market
Already understand the value of de-risked late-stage assets
This buyer convergence creates:
Shorter sales cycles (no market education needed)
Higher contract values (ROI is quantifiable: months saved = millions earned)
Strategic partnership opportunities (not just vendor relationships)
Workflow Maturity: AI Embedded Into the Real Job
One of the biggest mistakes AI startups make is selling AI as a product.
Formation Bio avoids this trap. In partnership with OpenAI and Sanofi, Formation Bio launched Muse, an AI tool designed to analyze scientific literature and generate tailored patient recruitment materials, cutting recruitment timelines from months to minutes.
Muse is embedded into Formation Bio’s trial acceleration workflow. Customers don’t buy “AI correlation.” They buy:
Lower trial costs → higher margin on out-licensed assets
Reduced execution risk → more predictable ROI
This is the key lesson for founders: AI becomes valuable when it disappears into the workflow and improves the business outcome.
If your customer has to stop, learn, reconfigure, and take on extra operational risk to use your product, your scenario maturity is low.
Data Maturity: The Closed Loop Most Startups Never Build
Most AI health startups face a “cold start” problem:
Data is fragmented across EHRs, wearables, and trials
Feedback loops are weak or non-existent
Model improvements don’t compound into business value
Formation Bio engineered a closed data loop:
Clinical trial execution → Real-world trial data → AI model iteration → Faster, cheaper next trial → Higher asset valuation
This creates:
Compounding advantage: Each trial makes the platform smarter
Defensible moat: Proprietary trial execution data can’t be scraped or replicated
Investor confidence: Clear path to margin expansion as the platform scales
This isn’t just a biotech story. It’s a scenario selection story — and it applies to every complex market.
The Kintsugi Contrast
This is why the contrast between Kintsugi and Formation Bio is so important.
Kintsugi had impressive technology: AI-based voice biomarkers for detecting depression. It had a compelling mission, clinical signal, and strong investor interest.
But the commercial scenario was much harder.
Who pays?
Hospitals?
Employers?
Health plans?
Digital health platforms?
Clinics?
Each buyer had different incentives, budgets, workflows, and risk concerns.
That created a scenario maturity gap.
Formation Bio, by contrast, chose a clearer buyer, a known pain point, a measurable ROI, and a workflow where AI could improve execution without requiring the whole market to change first.
That is the difference between promising technology and investable momentum.
Why This Matters for Every Tech Founder
Formation Bio’s lesson is universal: Success isn’t about better tech — it’s about smarter scenario selection.
Before you scale, ask:
Budget vs. Buzz: Is there an existing procurement line for your solution — or just interest?
Fit vs. Friction: Does your product plug into existing workflows, or require behaviour change?
Leverage vs. Labour: Does every customer make your system stronger — or add custom work?
Causation vs. Correlation: Can your buyer measure ROI in cost savings, revenue gains, or risk reduction?
If your technology is strong but revenue is slow, the problem may not be the product.
It may be your scenario maturity.
At Mans International, this is exactly what we help founders diagnose: where your product is getting stuck, why the market is not converting, and what must change before investors, customers, or strategic partners are ready to move.
Our expertise lies in Scenario Maturity Thinking — helping founders assess whether their technology is entering a market where the buyer, budget, urgency, data, and value-capture logic are mature enough to support real commercialization.
Because in today’s market, the winners are not always the companies with the most impressive technology.
They are the companies that know exactly where value is trapped, who has the incentive to unlock it, and how to convert that insight into revenue, partnership, and scale.
